| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | FORM S-8 |
| 04 Nov 2026 | FORM 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
ZUSDURI® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 09 Oct 2026 |
Form 4: Degnan Chris, Chief Financial Officer
Received 4,483 shares by exercise or conversion · Sold 2,202 shares ($80.8K) |
| 09 Oct 2026 | 144 |
| 09 Sep 2026 |
Form 4: Schoenberg Mark, Chief Medical Officer
Received 1,667 shares by exercise or conversion · Sold 871 shares ($37.4K) |
| 09 Sep 2026 |
Form 4: Smith Jason Drew, General Counsel
Received 3,334 shares by exercise or conversion · Sold 1,519 shares ($64.6K) |
| 09 Sep 2026 | 144 |
| 09 Sep 2026 | 144 |
| 28 Aug 2026 |
Form 4: Robinson James A. Jr., Director
Received 2,000 shares by exercise or conversion |
| 24 Aug 2026 |
Form 4: Schoenberg Mark, Chief Medical Officer
Sold 60,677 shares ($2.85M) |
| 20 Aug 2026 | 144 |
| 20 Aug 2026 |
8-K: Other Events
On August 18, 2026, UroGen Pharma Ltd. (“the Company”), through its wholly owned subsidiary UroGen Pharma, Inc. (“UroGen U.S.”), entered into an Option and Research License Agreement (the “Option Agreement”) with IntraGel Therapeutics, L... |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 | FORM 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
ZUSDURI® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth |
| 10 Jul 2026 |
Form 4: Schoenberg Mark, Chief Medical Officer
Sold 10,000 shares ($400K) |
| 09 Jul 2026 | 144 |
Loading...